ENLARGE Mylan CEO Heather Bresch holds up an EpiPen while testifying on Capitol Hill in Washington, D.C., on Sept. 21 before the House Oversight Committee hearing on EpiPen price increases. Photo: Pablo Martinez Monsivais/Associated PressWASHINGTON—The federal government says that Mylan NV has overcharged the federal-state Medicaid program by millions of dollars over five years for its emergency auto-injector product called the EpiPen. In doing so, Mr. Slavitt wrote, Mylan paid a smaller rebate of 13%, or about $163 million, when it should have been paying a rebate of 23.1% or more. After the rebate, Mr. Slavitt said, the net Medicaid spending on the product was about $797 million. Mylan said its product “meets the definition of ‘non-innovator’ drug in the Medicaid rebate law,” and that it has been classified that way since before Mylan acquired the product.

Source: Wall Street Journal October 05, 2016 23:10 UTC